The estimated Net Worth of Cheryl Cohen is at least $9.47 Milion dollars as of 11 August 2020. Ms. Cohen owns over 30,000 units of NantKwest Inc stock worth over $8,802,353 and over the last 9 years she sold NK stock worth over $300,725. In addition, she makes $368,414 as Director at NantKwest Inc.
Cheryl has made over 2 trades of the NantKwest Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 30,000 units of NK stock worth $298,800 on 11 August 2020.
The largest trade she's ever made was selling 30,000 units of NantKwest Inc stock on 11 August 2020 worth over $298,800. On average, Cheryl trades about 1,396 units every 29 days since 2015. As of 11 August 2020 she still owns at least 270,925 units of NantKwest Inc stock.
You can see the complete history of Ms. Cohen stock trades at the bottom of the page.
Cheryl L. Cohen is Director of the Company. She has served as President of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product start-up and commercialization, since 2008. Prior to CLC, Ms. Cohen served as Chief Commercial Officer of Medivation, Inc., a publicly traded bio-pharmaceutical company, from September 2011 until July 2014. From November 2007 to September 2008, she served as the Vice President, Strategic Commercial Group, of Health Care Systems, Inc., a Johnson & Johnson company, and from October 1998 to November 2007, she worked at Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.), a Johnson & Johnson company, in a variety of senior sales roles including Vice President, Rheumatology Franchise. Ms. Cohen has served on the board of Aerpio Pharmaceuticals, Inc., a pharmaceutical company, since 2018. Ms. Cohen also served on the board of Vital Therapies, Inc., a therapeutics company, from 2015 until 2019. Since 2015, Ms. Cohen has served on the board of Novus Therapeutics, Inc. (reverse merger of Tokai Pharmaceuticals, Inc.), a publicly traded pharmaceutical company focused on the acquisition, development, and commercialization of ear, nose, and throat products. Since April 2020, Ms. Cohen has served on the board of MEI Pharma, Inc., a publicly traded pharmaceutical company specializing in oncology. Ms. Cohen served on the board of Protein Sciences Corporation, a privately held bio-pharmaceutical company specializing in vaccine development from October 2014 to August 2017, and she served on the board of Cytrx Corporation, a publicly traded bio-pharmaceutical company specializing in oncology, from June 2015 through October 2016. Ms. Cohen began her career at Solvay Pharmaceuticals in a variety of sales positions. Ms. Cohen received her B.A. from Saint Joseph College
As the Director of NantKwest Inc, the total compensation of Cheryl Cohen at NantKwest Inc is $368,414. There are 2 executives at NantKwest Inc getting paid more, with Barry Simon having the highest compensation of $454,440.
Cheryl Cohen is 54, she's been the Director of NantKwest Inc since 2019. There are 5 older and 2 younger executives at NantKwest Inc. The oldest executive at NantKwest Inc is Frederick Driscoll, 69, who is the Lead Independent Director.
Cheryl's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 202, HAMPTON, NJ, 08827.
Over the last 9 years, insiders at NantKwest Inc have traded over $20,345,739 worth of NantKwest Inc stock and bought 4,163,265 units worth $55,365,252 . The most active insiders traders include Patrick Cambridge Equities,..., Steve Gorlin oraz Barry J. Simon. On average, NantKwest Inc executives and independent directors trade stock every 33 days with the average trade being worth of $5,362,832. The most recent stock trade was executed by Richard Adcock on 5 February 2021, trading 150,000 units of NK stock currently worth $4,873,500.
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
NantKwest Inc executives and other stock owners filed with the SEC include: